Minimal residual disease is “a credible intermediate endpoint” for some patients with newly diagnosed acute myeloid leukemia, researchers report.

In the second part of our interview with Fadi Haddad, MD, an assistant professor and co-leader of the Section of Chronic ...

The primary end point of the study, major molecular response at 12 months, was achieved by 69% of patients. Approximately a ...

The latest update is out from Enliven Therapeutics ( (ELVN) ).

In this video, Shazia K. Nakhoda, MD, discusses “exciting” data from the CLL-17 trial that showed fixed-duration therapy produces similar results inpreviously untreated chronic lymphocytic leukemia.Re ...

A small group of patients with an otherwise incurable form of T‑cell leukemia have seen their cancer driven into remission by ...

A breakthrough therapy is driving aggressive leukaemia into remission. Here’s what the headlines don’t tell you about life ...

In a new trial, the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib increased the rate of survival without disease progression and was well tolerated with a more favorable safety profile when ...

Discover why Terns Pharmaceuticals, Inc. stock is up 770% YTD with strong CML drug data and major upcoming milestones. Click ...

Terns soared to a new all-time high on Monday as investors took heart from the encouraging results of its clinical trial to ...

The presentation and publication of the BRUIN CLL-314 trial followed the FDA’s December 3 decision to expand approval for ...

Pirtobrutinib significantly improved PFS in previously untreated patients with chronic lymphocytic leukemia and small lymphocytic lymphoma compared with a standard chemoimmunotherapy regimen in a ...